IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
Share price
+$4.07 (+437.6%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
INTERPACE BIOSCIENCES, INC. saw revenue fall 20.5% to $36.14M over the twelve months to Jun 30, 2026. Operating income fell 27.2% to $4.17M, moving the operating margin from 12.6% to 11.5%. Free cash flow was $4.10M.
Revenue
$36.14M
-20.5% vs. a year earlier
Operating income
$4.17M
-27.2% vs. a year earlier
Free cash flow
$4.10M
TTM Q2 2026
EPS, diluted
$0.89
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $138.57M
- P/E ratio
- 5.6
- Price to sales
- 3.83
- Price to book
- 5.96
- Dividend yield
- –
- Free cash flow yield
- 2.96%
Fundamentals
- Revenue
- $36.14M
- Net income
- $24.45M
- EPS, diluted
- $0.89
- Free cash flow
- $4.10M
- Book value per share
- $0.84
- Diluted shares
- 28M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$36.14M-20.5% YoY
Gross profit
$23.04M-19.0% YoY
Operating income
$4.17M-27.2% YoY
Net income
$24.45M+435.6% YoY
EPS, diluted
$0.89
Free cash flow
$4.10M
Reported periodTrailing twelve months